Mindset Pharma (OTCMKTS:MSSTF – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both healthcare companies, but which is the superior investment? Get Mindset Pharma alerts:Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mindset Pharma 0 0 0 0 0.00 CRISPR Therapeutics 1 7 10 1 2.58CRISPR Therapeutics has a consensus price target of $68.06, suggesting a potential upside of 27.16%. Given CRISPR Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Mindset Pharma. Net Margins Return on Equity Return on Assets Mindset Pharma N/A N/A N/A CRISPR Therapeutics -3,368.72% -24.39% -18.25%Valuation & EarningsThis table compares Mindset Pharma and CRISPR Therapeutics”s revenue, earnings per share (EPS) and valuation. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.